all report title image

A number of different tests can be used to check human immunodeficiency virus (HIV). These tests can be performed on blood samples or saliva samples. Blood samples can be obtained via an in-office finger prick or a blood draw in a laboratory. According to test type, the market is divided into three categories which includes screening, differentiation & confirmation test, and monitoring test. Antibody detection can be done using an enzyme-linked immunosorbent assay (ELISA) test, rapid test, and western blot test, in order to detect HIV infection. These tests are used as screening tests and/or confirmatory tests. HIV differentiation and confirmation tests are performed using western blot and immunofluorescence assay (IFA) methods. Monitoring testes includes CD4 count (is used to assess a patient’s immunologic response to antiretroviral treatment (ART) and Viral load tests (are used to quantify the amount of HIV-1 RNA circulating in the blood of an infected individual).

The global HIV diagnostics test market is estimated to be valued at US$ 4,263.62 million in 2022 and expected to reach US$ 8,487.17 million by 2030, witnessing a CAGR of 9.0% over the forecast period (2022-2030).

Figure 1. Global HIV Diagnostics Test Market Share (%), By Region, 2022

HIV Diagnostics Test  | Coherent Market Insights

Rising government initiatives for increasing the number of HIV diagnostics test is expected to drive the growth of the global HIV diagnostics test market.

For instance, in 2020, Egypt government announced that it is offering free and confidential HIV diagnostics test at the examinations and counselling centers in all of the country’s 27 governorates.

Since the start of the COVID-19 pandemic, the Egypt government had been investing significantly to provide health services to all patients, especially those with chronic diseases including AIDS patients. Moreover, according to the Ministry of Health Saudi Arabia, the Ministry of Health (MoH) spent around US$ 71 billion in 2020 on healthcare awareness programs in Saudi Arabia.

According to a recent Gulf Cooperation Council (GCC) report published on June 27, 2021, Saudi Arabia plans to invest US$ 66.67 billion in healthcare infrastructure and boost private sector participation from 40% to 65% by 2030 in Saudi Arabia healthcare market.

CMI table icon

HIV Diagnostics Test Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 4,263.62 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 9.0% 2030 Value Projection: US$ 8,487.17 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Test Type: Screening (Third Generation (Antibody Test) { Laboratory-based, Point-of-Care}, Fourth Generation (Antibody Test) { Laboratory-based, Point-of-Care}, Others), Differentiation & Confirmation Test, Monitoring Test (CD4 Test, Viral Load Tests)
Companies covered:

Abbott, Bio-Rad Laboratories, Inc., Hologic, Inc., Siemens Healthineers, Roche AG, Beckman Coulter Inc., OraSure Technologies, Inc., Becton, Dickinson and Company, Merck KGaA, Chembio Diagnostic Systems, Inc., Zyomyx Incorporation, Bristol –Myers Squibb, Janssen Pharmaceutica NV, QIAGEN N.V., and ViiV Healthcare Ltd.

Growth Drivers:
  • Increasing number of blood transfusion and donations
  • Government initiatives taken to reduce the HIV/AIDS burden
Restraints & Challenges:
  • HIV stigmatization
  • Inadequacy of HIV reagents & kits

Figure 2. Global HIV Diagnostics Test Market Share (%) Analysis, By Test Type, 2022

HIV Diagnostics Test  | Coherent Market Insights

Increasing launch and development of technologically advanced HIV diagnostics test is expected to drive the growth of the global HIV diagnostics test market.

Key players operating in the market are focusing on the development and launch of technologically advanced HIV diagnostics test in order to expand their product portfolio and presence in the global market. For instance, in 2020, F. Hoffmann-La Roche AG, a Swiss multinational healthcare company, launched Elecsys HIV Duo immunoassay in the U.S., after it received approval from the U.S Food and Drug Administration (U.S. FDA) in April 2020. Elecsys HIV Duo is the first 4th generation HIV testing solution in the U.S. that allows separate detection of HIV p24 antigen and anti-HIV antibodies.

Moreover, in 2018, Abbott, a medical device and healthcare company, launched new point-of-care test called m-PIMA HIV-1/2 VL in The Netherlands. The test helps in the detection of HIV infection among the patients.

Global HIV Diagnostics Test Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries across the globe. The coronavirus (COVID 19) pandemic and consequent lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Supply chain and manufacturing activities have been disrupted globally, due to lockdowns implemented by governments, restricted movement, and other COVID-19 safety precautions. Demand for HIV diagnostics test is expected to decrease during the pandemic.

According to a retrospective cohort study published by the John Wiley & Sons, Inc., in October 2021, using secondary data from the AIDS Healthcare Foundation (AHF) Global Quality Program from 44 countries in four continents (Asia, Latin America and the Caribbean, Europe and Africa), it was found that COVID-19 was associated with a significant reduction in HIV testing, an increase in the percentage of positive tests, a reduction in the number of in-person consultations and a reduction in the number of new enrolments in care, despite the implementation of several mitigation strategies. The impact of COVID-19 differed across continents and key populations.

Global HIV Diagnostics Test Market: Restraint

HIV stigmatization and inadequacy of HIV reagents & kits may act as a restraint for the growth of the global HIV diagnostics test market. For instance, according to Centers for Disease Control and Prevention (CDC), HIV stigma refers to irrational or negative attitudes, behavior, and judgments towards HIV-positive or HIV-infected people. It can have a negative impact on persons living with HIV's health and well-being by discouraging some people from knowing their HIV status, getting treatment, or staying in care.

Key Players

Major players operating in the global HIV diagnostics test market include Abbott, Bio-Rad Laboratories, Inc., Hologic, Inc., Siemens Healthineers, Roche AG, Beckman Coulter Inc., OraSure Technologies, Inc., Becton, Dickinson and Company, Merck KGaA, Chembio Diagnostic Systems, Inc., Zyomyx Incorporation, Bristol –Myers Squibb, Janssen Pharmaceutica NV, QIAGEN N.V., and ViiV Healthcare Ltd.

Human immunodeficiency virus (HIV) is an infection that attacks the body's immune system, specifically the white blood cells called CD4 cells. HIV destroys these CD4 cells, weakening a person’s immunity against opportunistic infections, such as tuberculosis and fungal infections, severe bacterial infections and some cancers. The World Health Organization (WHO) recommends that every person who may be at risk of HIV should access testing. People at increased risk of acquiring HIV should seek comprehensive and effective HIV prevention, testing and treatment services. HIV diagnostics plays a major role in HIV prevention, treatment, care, and other support services. The diagnosis of HIV include testing services in health-care facilities, and wide range of community-based approaches along with HIV self-testing.

Market Dynamics

The increasing prevalence of HIV infections globally is expected to drive the market growth in the forecast period. For instance, according to the Pan American Health Organization (PAHO): 2020, the number of HIV infections increased by 21% from 2010 and 2019 in Latin America. According to the same source, the number of annual new infections continued to rise, reaching 120,000 in 2019. According to UNAIDS: AIDSinfo: 2018, in India, around 2.1 million people were suffering from HIV during 2017, making it the third-largest HIV epidemic in the world. Furthermore, as per UNAIDS: 2017; India’s HIV epidemic had slowed down, as HIV infections declined by 27% and AIDS-related deaths reduced by more than 56% between 2010 and 2017. However, in 2017, new infections increased to 88,000 from 80,000 and AIDS-related deaths increased to 69,000 from 62,000, from the year 2010, in India.

Key features of the study:

  • This report provides an in-depth analysis of the global HIV diagnostics test market, market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global HIV diagnostics test market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
  • Key companies covered as a part of this study include Abbott, Bio-Rad Laboratories, Inc., Hologic, Inc., Siemens Healthineers, Roche AG, Beckman Coulter Inc., OraSure Technologies, Inc., Becton, Dickinson and Company, Merck KGaA, Chembio Diagnostic Systems, Inc., Zyomyx Incorporation, Bristol –Myers Squibb, Janssen Pharmaceutica NV, QIAGEN N.V., and ViiV Healthcare Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global HIV diagnostics test market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global HIV diagnostics test market

Detailed Segmentation:

  • Global HIV Diagnostics Test Market, By Test Type:
    • Screening
      • Third Generation (Antibody Test)
        • Laboratory-based
        • Point-of-Care
      • Fourth Generation (Antibody Test)
        • Laboratory-based
        • Point-of-Care
      • Others
    • Differentiation & Confirmation Test
    • Monitoring Test
      • CD4 Test
      • Viral Load Tests
  • Global HIV Diagnostics Test Market, By Region:        
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Abbott
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Bio-Rad Laboratories, Inc.
    • Hologic, Inc.
    • Siemens Healthineers
    • Roche AG
    • Beckman Coulter Inc.
    • OraSure Technologies, Inc.
    • Becton, Dickinson and Company
    • Merck KGaA
    • Chembio Diagnostic Systems, Inc.
    • Zyomyx Incorporation
    • Bristol –Myers Squibb
    • Janssen Pharmaceutica NV
    • QIAGEN N.V.
    • ViiV Healthcare Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global HIV diagnostics test market is estimated to be valued at US$ 4,263.62 Million in 2022 and expected to exhibit a CAGR of 9.0% between 2022 and 2030.
Increasing number of blood transfusion and donations, government initiatives taken to reduce the HIV/AIDS burden are major growth driving factors for the market.
Screening is the major test type segment owing to continuing technological development in HIV screening devices.
HIV stigmatization and inadequacy of HIV reagents & kits are the major factor restraining the market growth.
Major players operating in the market include Abbott, Bio-Rad Laboratories, Inc., Hologic, Inc., Siemens Healthineers, Roche AG, Beckman Coulter Inc., OraSure Technologies, Inc., Becton, Dickinson and Company, Merck KGaA, Chembio Diagnostic Systems, Inc., Zyomyx Incorporation, Bristol –Myers Squibb, Janssen Pharmaceutica NV, QIAGEN N.V., and ViiV Healthcare Ltd.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo